Press Releases

New Treatment for Tumors That Are Considered Inoperable BETHESDA, MD, September 20, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is in late stage discussions with medical centers in the U.S. and Europe to proceed with a Phase I/II clinical trial with the Company’s third major product line, DCVax®-Direct, for all... Read More

Executive Responsible for Commercializing Multiple Drugs BETHESDA, MD, September 18, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has appointed former pharmaceutical industry executive Dr. Günter Rosskamp as the CEO of the Company’s German subsidiary, Northwest Biotherapeutics, Gmbh. Dr. Rosskamp brings extensive... Read More

NW Bio Now in Phase III Clinical Trial for Brain Cancer in Both the U.S. and Europe BETHESDA, MD, August 23, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (the U.K.’s “FDA”), for the Company’s 300-patient Phase III clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme brain... Read More

US Capacity Doubling, and European Capacity Coming On Line BETHESDA, MD, August 8, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio or the Company) announced today that it is entering into amended agreements to double the production capacity in the U.S. for the manufacture of the Company’s DCVax®-L immune therapy for Glioblastoma multiforme (GBM) patients. Manufacturing is also commencing in Europe, with production already fully... Read More

Culmination of Nearly 18-Month Process, In Close Collaboration With Northwest Bio and Cognate BioServices BETHESDA, MD, July 25, 2012 — Northwest Biotherapeutics, Inc. (OTC.BB: NWBO) (the “Company” or “Northwest Bio”) announced today that its partner in Germany, Fraunhofer IZI, has received the official approval and certification from the regional and national regulatory agencies in Germany (including the Paul-Ehrlich-Institut, or P... Read More